Year-end Sale % OFF 
Abstract
It is known that in diabetic patients with microangiopathy, the potency of blood coagulation and thromboxane production are activated. A specific thromboxane synthetase inhibitor, OKY-046 was given to 15 diabetic patients to study its effects on platelets, blood coagulation-fibrinolysis and renal function.Plasma thromboxane B2 tended to decrease after administration of OKY-046. Plasma 6-keto PGF1α indicated a significant increase after 1 month. Plasma thromboxane B2/6-keto PGF1α ratio showed a significant decrease after 2 weeks, with a gradual increase thereafter. Urinary thromboxane B2 also showed a significant decrease after 2 months. As the renal function, urinary β2-microglobulin (β2MG) showed a significant decrease after 2 months. In view of urinary β2MG and NAG levels which are said to be the early indices of nephropathy, OKY-046 was markedly effective in 3 cases, effective in 10 cases, ineffective in 2 cases and no aggravation. In view of blood β2MG which is said to reflect glomerular filtration rate, the drug was markedly effective in 2 cases, effective in 1 case and ineffective in 12 cases with no aggravation.We conclude that OKY-046 suppresses thromboxane production, activates PGI2 production and reduces thromboxane B2/6-keto PGF1α ratio in diabetic patients, suggesting to have an effect to improve diabetic nephropathy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
